CellaVision AB (publ) (LON:0MR5)
United Kingdom · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 364.05M +16.0% |
| Revenue (ttm) | 57.57M +1.9% |
| Net Income | 10.41M -8.9% |
| EPS | 0.44 -8.9% |
| Shares Out | n/a |
| PE Ratio | 34.95 |
| Forward PE | 26.95 |
| Dividend | 0.22 (1.43%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 1,166 |
| Open | 203.50 |
| Previous Close | 201.50 |
| Day's Range | 203.50 - 204.00 |
| 52-Week Range | 118.80 - 202.10 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and Cella... [Read more]
Financial Performance
In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.
Financial numbers in SEK Financial StatementsNews
CellaVision AB Earnings Call Transcript: Q3 2026
Q3 sales rose 13.6% to SEK 200m, with 32% growth in the Americas and 91% organic growth in APAC; EBITDA margin was 32%. Bone marrow adoption and recurring reagent momentum advanced, while China and EMEA healthcare spending remain headwinds.
CellaVision AB Quarterly report: Q3 2026
CellaVision AB has published its Q3 2026 quarterly earnings report on October 29, 2026.
CellaVision AB Slides: Q3 2026
CellaVision AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
CellaVision AB Earnings Call Transcript: Q2 2026
Q2 2026 delivered solid growth with net sales up 4.5% and record performance in the Americas, while EMEA stabilized and APAC saw strong reagent sales despite China headwinds. EBITDA margin was 27%, and the Bone Marrow Application launch and FDA progress support future growth.
CellaVision AB Quarterly report: Q2 2026
CellaVision AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
CellaVision AB Slides: Q2 2026
CellaVision AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Cellavision downgraded to Hold from Buy at Pareto
Pareto downgraded Cellavision (CLVSF) to Hold from Buy with a SEK 150 price target
CellaVision AB Earnings Call Transcript: Q1 2026
Q1 revenue fell 14.6% year-over-year due to EMEA inventory adjustments, while Americas and APAC delivered strong growth. New product launches and a major software upgrade are expected to drive H2 recovery, with EMEA sales seen improving in Q2.
CellaVision AB Quarterly report: Q1 2026
CellaVision AB has published its Q1 2026 quarterly earnings report on April 24, 2026.
CellaVision AB Slides: Q1 2026
CellaVision AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 24, 2026.
CellaVision AB Earnings Call Transcript: Q4 2025
Q4 2025 saw robust growth in the Americas and EMEA, offsetting a softer APAC, with full-year organic growth at 9%. Strategic milestones included a CE Mark for the bone marrow application and a major software upgrade, while a dividend increase to SEK 2.75 per share is proposed.
CellaVision AB Annual report: Q4 2025
CellaVision AB has published its Q4 2025 annual report on February 5, 2026.
CellaVision AB Quarterly report: Q4 2025
CellaVision AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
CellaVision AB Slides: Q4 2025
CellaVision AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.